Log in
Enquire now
‌

US Patent 10238753 Antisense conjugates for decreasing expression of DMPK

Patent 10238753 was granted and assigned to Valerion Therapeutics on March, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Valerion Therapeutics
Valerion Therapeutics
0
Current Assignee
Valerion Therapeutics
Valerion Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
102387530
Patent Inventor Names
Dustin D. Armstrong0
Date of Patent
March 26, 2019
0
Patent Application Number
154740030
Date Filed
March 30, 2017
0
Patent Citations Received
‌
US Patent 12128109 Muscle targeting complexes and formulations for treating dystrophinopathies
0
‌
US Patent 12005124 Muscle targeting complexes and uses thereof for treating dystrophinopathies
0
‌
US Patent 12012460 Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
0
‌
US Patent 12018087 Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
0
‌
US Patent 12102687 Muscle targeting complexes and uses thereof for treating myotonic dystrophy
0
‌
US Patent 11629197 Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness
0
‌
US Patent 11633498 Muscle targeting complexes and uses thereof for treating myotonic dystrophy
0
‌
US Patent 11633496 Muscle targeting complexes and uses thereof for treating dystrophinopathies
0
...
Patent Primary Examiner
‌
Kimberly Chong
0
Patent abstract

The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10238753 Antisense conjugates for decreasing expression of DMPK

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.